An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to ...

After a nine-month investigation into direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer, a group of ...

The opportunity to “ talk to a doctor now ” increases access to care, the drug companies say. But the legislators, and some ...

Senators led by Sen. Dick Durbin (D-Ill.) on Monday demanded answers from Pfizer and Eli Lilly about their relationship with the telehealth prescribers they point patients to from their websites ...

April 23 (UPI) --Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling compounds of slightly-different versions of Lilly drugs ...

Mr. Ricks said that Eli Lilly does not compensate doctors who prescribe its medications through Form, the telehealth platform connected to LillyDirect, and that these doctors have no knowledge ...

Telehealth partners for Eli Lilly (LLY) continue to sell compounded GLP-1 weight-loss drugs despite an agreement with the pharma giant to end copycat sales after the FDA ended a years-long ...

Eli Lilly & Co. is suing four telehealth companies selling compounded versions of tirzepatide, the active ingredient in Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro.

On Wednesday, pharmaceutical giant Eli Lilly sued four prominent telehealth companies that offer more affordable, off-brand versions of its patented best-selling GLP-1 medications Mounjaro and ...

Lilly Pacts Prohibit Telehealth Sales of Copycat Zepbound An Eli Lilly & Co. Zepbound injection pens. Photographer: Shelby Knowles/Bloomberg By Madison Muller June 10, 2025 at 9:57 AM PDT ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...

Telehealth partners for Eli Lilly (LLY) continue to sell compounded GLP-1 weight-loss drugs despite an agreement with the pharma giant to end copycat sales after the FDA ended a years-long ...